STOCK TITAN
  1. Home
  2. Sec-filings
  3. AGIO
  4. [Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity

Agios (AGIO) Director Reports 10b5-1 Trades and Option Holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

David Scadden, a director of Agios Pharmaceuticals (AGIO), reported trading activity executed on 09/30/2025 under a Rule 10b5-1 trading plan. The filing shows a purchase of 200 common shares at $18.09 and a sale of 200 common shares at $40.00 on the same date. After those transactions Mr. Scadden reported beneficial ownership of 17,603 shares of common stock and, including derivative holdings, 27,307 shares underlying options.

The Form 4 also reports an option grant with an exercise price of $18.09 and an expiration date of 06/21/2032. The filer notes the option grant was originally made on 06/21/2022 and that the underlying shares vest 100% one year from the grant date. The filing is signed by an attorney-in-fact on 10/02/2025.

Positive

  • None.

Negative

  • None.

Insights

Director traded both buys and sells under a Rule 10b5-1 plan on 09/30/2025

The filing documents a 200-share purchase at $18.09 and a 200-share sale at $40.00 executed the same day under a Rule 10b5-1 plan, which indicates pre-scheduled transactions rather than ad hoc trades.

The report also increases the director's total reported economic exposure to 27,307 shares when counting options with a $18.09 exercise price that expire on 06/21/2032. The plan disclosure and option details are relevant for assessing compliance and the director's ongoing stake.

Insider Scadden David
Role Director
Sold 200 shs ($8K)
Type Security Shares Price Value
Exercise Stock options (right to buy) 200 $0.00 --
Exercise Common stock 200 $18.09 $4K
Sale Common stock 200 $40.00 $8K
Holdings After Transaction: Stock options (right to buy) — 27,307 shares (Direct); Common stock — 17,803 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Scadden David
(Last) (First) (Middle)
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 09/30/2025 M(1) 200 A $18.09 17,803 D
Common stock 09/30/2025 S(1) 200 D $40 17,603 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (right to buy) $18.09 09/30/2025 M(1) 200 (2) 06/21/2032 Common stock 200 $0 27,307 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.
Remarks:
/s/ William Cook, as Attorney-in-fact for David Scadden 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who filed the Form 4 for AGIO?

David Scadden, a director of Agios Pharmaceuticals (AGIO), filed the Form 4 via attorney-in-fact on 10/02/2025.

What trades did the reporting person make on 09/30/2025?

The filing shows a purchase of 200 common shares at $18.09 and a sale of 200 common shares at $40.00 executed on 09/30/2025.

Were the trades part of a prearranged plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What derivative holdings are reported for the reporting person?

The Form 4 reports an option with an $18.09 exercise price and an expiration date of 06/21/2032, and total underlying shares reported following the transaction of 27,307.

How many shares does David Scadden beneficially own after these transactions?

The filing reports 17,603 shares of common stock held directly after the reported transactions.